Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945824 | 0.88 | SIGMAR1 (0.55) | SIGMAR1HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL9945825 | 0.87 | SIGMAR1 (0.54) | SIGMAR1HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL9945828 | 0.84 | SIGMAR1 (0.51) | SIGMAR1HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL9945827 | 0.84 | SIGMAR1 (0.51) | SIGMAR1HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL6001689 | 0.77 | — | — | |
| SCHEMBL6001686 | 0.77 | — | — | |
| SCHEMBL6001937 | 0.75 | GRIN2B (0.56) | HTR2AHTR2CHTR2BGRIN2B | |
| SCHEMBL809935 | 0.74 | ALDH1A1 (0.43) | SIGMAR1HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL11881965 | 0.71 | SIGMAR1 (0.66) | SIGMAR1HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL11642135 | 0.70 | PRCP (0.50) | SIGMAR1HTR2AHTR2CHTR2BSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017458-B2 | Therapeutic tetrahydronaphthalene compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017458-B2 | Therapeutic tetrahydronaphthalene compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-07-10 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | SIGMAR1 1254/4885HTR2A 7/4885HTR2C 1/4885 |
| US-10017458-B2 | Therapeutic tetrahydronaphthalene compounds | HTR2C, HTR2A, HTR3C | SIGMAR1 1155/4885HTR2A 2/4885HTR2C 1/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | SIGMAR1 1254/4885HTR2A 7/4885HTR2C 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.